Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Christopher MaS J DuttonL E CiprianoSiddharth SinghC E ParkerT M NguyenL GuizzettiJ C GregorN ChandeP HindryckxBrian G FeaganVipul JairathPublished in: Alimentary pharmacology & therapeutics (2018)
Over one-third of CD patients entering clinical trials are still co-prescribed aminosalicylates. A definitive trial is needed to inform the conventional practice of using aminosalicylates as CD maintenance therapy.
Keyphrases
- risk factors
- clinical trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- primary care
- chronic kidney disease
- healthcare
- peritoneal dialysis
- phase ii
- prognostic factors
- randomized controlled trial
- stem cells
- nk cells
- mesenchymal stem cells
- quality improvement
- patient reported
- open label
- double blind
- cell therapy
- replacement therapy